NOVOSEVEN RT eptacog alfa (activated) (bhk) 8mg powder for injection vial with pre-filled diluent syringe Australia - English - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 8mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 12.57 mg - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 5mg powder for injection vial with pre-filled diluent syringe Australia - English - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 5mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 8.01 mg - injection - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe Australia - English - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 3.26 mg - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients: with inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN RT eptacog alfa (activated) (bhk) 1mg powder for injection vial with pre-filled diluent syringe Australia - English - Department of Health (Therapeutic Goods Administration)

novoseven rt eptacog alfa (activated) (bhk) 1mg powder for injection vial with pre-filled diluent syringe

novo nordisk pharmaceuticals pty ltd - histidine, quantity: 1.74 mg - injection - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - novoseven rt is indicated for the control of bleeding and surgical prophylaxis in patients with: inhibitors to coagulation factors viii or ix; with congenital fvii deficiency; with glanzmann's thrombasthenia, who have antibodies to gpiib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

NOVOSEVEN  RT 1 MGVIAL Israel - English - Ministry of Health

novoseven rt 1 mgvial

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

NOVOSEVEN  RT 2 MGVIAL Israel - English - Ministry of Health

novoseven rt 2 mgvial

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

NOVOSEVEN  RT 5 MGVIAL Israel - English - Ministry of Health

novoseven rt 5 mgvial

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

Ilvico Cold and Flu film-coated tablets Paracetamol 325 mg Caffeine 30 mg Brompheniramine maleate 3 mg Ireland - English - HPRA (Health Products Regulatory Authority)

ilvico cold and flu film-coated tablets paracetamol 325 mg caffeine 30 mg brompheniramine maleate 3 mg

seven seas ltd - paracetamol; brompheniramine maleate; caffeine - film-coated tablet - 325 / 30 / 3 milligram(s) - substituted alkylamines; brompheniramine, combinations

VAXSAFE ND VACCINE (LIVING) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxsafe nd vaccine (living)

bioproperties pty. ltd. - newcastle disease strain v-4 virus - misc. vaccines or anti sera - newcastle disease strain v-4 virus vaccine-viral active 0.0 eid 50/d - immunotherapy - poultry broilers (meat for human consum) | chickens | chooks | meat birds - newcastle disease